|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2007. CA Cancer J Clin. 57:43–66. 2007.
|
|
2
|
McGuire WP, Hoskins WJ, Brady MF, et al:
Cyclophosphamide and cisplatin compared with paclitaxel and
cisplatin in patients with stage III and stage IV ovarian cancer. N
Engl J Med. 334:1–6. 1996.
|
|
3
|
Ozols RF, Bundy BN, Greer BE, et al;
Gynecologic Oncology Group. Phase III trial of carboplatin and
paclitaxel compared with cisplatin and paclitaxel in patients with
optimally resected stage III ovarian cancer: a Gynecologic Oncology
Group study. J Clin Oncol. 21:3194–3200. 2003.
|
|
4
|
Mutch DG: Gemcitabine combination
chemotherapy of ovarian cancer. Gynecol Oncol. 90:S16–S20.
2003.
|
|
5
|
Ozols RF: Systemic therapy for ovarian
cancer: current status and new treatments. Semin Oncol. 33(Suppl
6): S3–S11. 2006.
|
|
6
|
Bookman MA, Brady MF, McGuire WP, et al:
Evaluation of new platinum-based treatment regimens in
advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic
Cancer Intergroup. J Clin Oncol. 27:1419–1425. 2009.
|
|
7
|
Stordal B, Pavlakis N and Davey R: A
systematic review of platinum and taxane resistance from bench to
clinic: an inverse relationship. Cancer Treat Rev. 33:688–703.
2007.
|
|
8
|
Markman M, Webster K, Zanotti K, et al:
Survival following the documentation of platinum and taxane
resistance in ovarian cancer: a single institution experience
involving multiple phase 2 clinical trials. Gynecol Oncol.
93:699–701. 2004.
|
|
9
|
Pavelka M, Lucas M and Russo N: On the
hydrolysis mechanism of the second-generation anticancer drug
carboplatin. Chemistry. 13:10108–10116. 2007.
|
|
10
|
Agarwal R and Kaye SB: Ovarian cancer:
strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003.
|
|
11
|
Cheng TC, Manorek G, Samimi G, et al:
Identification of genes whose expression is associated with
cisplatin resistance in human ovarian carcinoma cells. Cancer
Chemother Pharmacol. 58:384–395. 2006.
|
|
12
|
Rabik CA and Dolan ME: Molecular
mechanisms of resistance and toxicity associated with platinating
agents. Cancer Treat Rev. 33:9–23. 2007.
|
|
13
|
Roberts D, Schick J, Conway S, et al:
Identification of genes associated with platinum drug sensitivity
and resistance in human ovarian cancer cells. Br J Cancer.
92:1149–1158. 2005.
|
|
14
|
Peters D, Freund J and Ochs RL:
Genome-wide transcriptional analysis of carboplatin response in
chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer
Ther. 4:1605–1616. 2005.
|
|
15
|
Johnatty SE, Beesley J, Paul J, et al:
ABCB1 (MDR 1) polymorphisms and progression-free survival among
women with ovarian cancer following paclitaxel/carboplatin
chemotherapy. Clin Cancer Res. 14:5594–5601. 2008.
|
|
16
|
Walters MR: Newly identified actions of
the vitamin D endocrine system. Endocrinol Rev. 13:719–764.
1992.
|
|
17
|
Saunders DE, Christensen C, Williams JR,
et al: Inhibition of breast and ovarian carcinoma cell growth by
1,25-dihydroxyvitamin D3 combined with retinoic acid or
dexamethasone. Anticancer Drugs. 6:562–569. 1995.
|
|
18
|
Majewski S, Szmurlo A, Marczak M, et al:
Inhibition of tumor cell-induced angiogenesis by retinoids,
1,25-dihydroxyvitamin D3 and their combination. Cancer Lett.
75:35–39. 1993.
|
|
19
|
Koli K and Keski-Oja J:
1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell
invasion-associated proteases in cultured malignant cells. Cell
Growth Differ. 11:221–229. 2000.
|
|
20
|
Evans SR, Shchepotin EI, Young H, et al:
1,25-dihydroxyvitamin D3 synthetic analogs inhibit spontaneous
metastases in a 1,2-dimethylhydrazine-induced colon carcinogenesis
model. Int J Oncol. 16:1249–1254. 2000.
|
|
21
|
Peterlik M, Grant WB and Cross HS:
Calcium, vitamin D and cancer. Anticancer Res. 29:3687–3698.
2009.
|
|
22
|
Akhter J, Chen X, Bowrey P, et al: Vitamin
D3 analog, EB1089, inhibits growth of subcutaneous xenographs of
the human colon cancer cell line, LoVo, in nude mouse model. Dis
Colon Rectum. 40:317–321. 1997.
|
|
23
|
VanWeelden KV, Flanagan L, Binderup L, et
al: Apoptotic regression of MCF-7 xenografts in nude mice treated
with the vitamin D3 analog, EB1089. Endocrinology. 139:2102–2110.
1998.
|
|
24
|
Mehta RG and Mehta RR: Vitamin D and
cancer. J Nutr Biochem. 13:252–264. 2002.
|
|
25
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984.
|
|
26
|
Soriano AF, Helfrich B, Chan DC, et al:
Synergistic effects of new chemopreventive agents and conventional
cytotoxic agents against human lung cancer cell lines. Cancer Res.
59:6178–6184. 1999.
|
|
27
|
Smiley ST, Reers M, Mottola-Hartshorn C,
et al: Intracellular heterogeneity in mitochondrial membrane
potentials revealed by a J-aggregate-forming lipophilic cation
JC-1. Proc Natl Acad Sci USA. 88:3671–3675. 1991.
|
|
28
|
Sung DK, Chang YS, Kang S, et al:
Comparative evaluation of hypoxic-ischemic brain injury by flow
cytometric analysis of mitochondrial membrane potential with JC-1
in neonatal rats. J Neurosci Methods. 193:232–238. 2010.
|
|
29
|
Turturro F, Friday E and Welbourne T:
Hyperglycemia regulates thioredoxin-ROS activity through induction
of thioredoxin-interacting protein (TXNIP) in metastatic breast
cancer-derived cells MDA-MB-231. BMC Cancer. 7:962007.
|
|
30
|
Johnson JA, Grande JP, Windebank AJ and
Kumar R: 1,25-Dihydroxyvitamin D(3) receptors in developing dorsal
root ganglia of fetal rats. Brain Res Dev Brain Res. 92:120–124.
1996.
|
|
31
|
Dokoh S, Donaldson CA, Marion SL, et al:
The ovary: a target organ for 1,25-dihydroxyvitamin D3.
Endocrinology. 112:200–206. 1983.
|
|
32
|
Ahonen MH, Zhuang YH, Aine R, et al:
Androgen receptor and vitamin D receptor in human ovarian cancer:
growth stimulation and inhibition by ligands. Int J Cancer.
86:40–46. 2000.
|
|
33
|
Saunders DE, Christensen C, Lawrence WD,
et al: Receptors for 1,25-dihydroxyvitamin D3 in gynecologic
neoplasms. Gynecol Oncol. 44:131–136. 1992.
|
|
34
|
Garland CF, Garland FC, Gorham ED, et al:
The role of vitamin D in cancer prevention. Am J Public Health.
96:252–261. 2006.
|
|
35
|
Grant WB: An estimate of premature cancer
mortality in the U.S. due to inadequate doses of solar
ultraviolet-B radiation. Cancer. 94:1867–1875. 2002.
|
|
36
|
Bidoli E, La Vecchia C, Talamini R, et al:
Micronutrients and ovarian cancer: a case-control study in Italy.
Ann Oncol. 12:1589–1593. 2001.
|
|
37
|
Salazar-Martinez E, Lazcano-Ponce EC,
Gonzalez Lira-Lira G, et al: Nutritional determinants of epithelial
ovarian cancer risk: a case-control study in Mexico. Oncology.
63:151–157. 2002.
|
|
38
|
Moffatt KA, Johannes W and Miller GJ:
1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically
to inhibit the growth of prostate cancer cell lines. Clin Cancer
Res. 5:695–703. 1999.
|
|
39
|
Jiang F, Li P, Fornace AJ Jr, et al: G2/M
arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated
through the induction of GADD45 via an exhonic enhancer. J Biol
Chem. 278:48030–48040. 2003.
|
|
40
|
Li P, Li C, Zhao X, et al: p27(Kip1)
stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in
ovarian cancer cells mediated through down-regulation of cyclin
E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2
ubiquitin ligase. J Biol Chem. 279:25260–25267. 2004.
|
|
41
|
Cho YL, Christensen C, Saunders DE, et al:
Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on
the growth of MCF-7 cells. Cancer Res. 51:2848–2853. 1991.
|
|
42
|
Light BW, Yu W, McElwain MC, et al:
Potentiation of cisplatin antitumor activity using a vitamin D
analogue in a murine squamous cell carcinoma system. Cancer Res.
57:3759–3764. 1997.
|
|
43
|
Koren R, Hadari-Naor I, Zuck E, et al:
Vitamin D is a prooxidant in breast cancer cells. Cancer Res.
61:1439–1444. 2001.
|
|
44
|
Wiseman H: Vitamin D is a membrane
antioxidant. Ability to inhibit iron-dependent lipid peroxidation
in liposomes compared to cholesterol, ergosterol and tamoxifen and
relevance to anticancer action. FEBS Lett. 326:285–288. 1993.
|
|
45
|
Poulsen HE, Prieme H and Loft S: Role of
oxidative DNA damage in cancer initiation and promotion. Eur J
Cancer Prev. 7:9–16. 1998.
|
|
46
|
Marchionatti AM, Picotto G, Narvaez CJ, et
al: Antiproliferative action of menadione and
1,25(OH)2D3 on breast cancer cells. J Steroid
Biochem Mol Biol. 113:227–232. 2009.
|
|
47
|
Koren R, Rocker D, Kotestiano O, et al:
Synergistic anticancer activity of 1,25-dihydroxyvitamin D(3) and
immune cytokines: the involvement of reactive oxygen species. J
Steroid Biochem Mol Biol. 73:105–112. 2000.
|
|
48
|
Bao BY, Ting HJ, Hsu JW and Lee YF:
Protective role of 1 alpha, 25-dihydroxyvitamin D3 against
oxidative stress in nonmalignant human prostate epithelial cells.
Int J Cancer. 122:2699–2706. 2008.
|
|
49
|
Chen WJ, Huang YT, Wu ML, et al: Induction
of apoptosis by vitamin D2, ergocalciferol, via reactive oxygen
species generation, glutathione depletion, and caspase activation
in human leukemia cells. J Agric Food Chem. 56:2996–3005. 2008.
|
|
50
|
Weitsman GE, Ravid A, Liberman UA and
Koren R: Vitamin D enhances caspase-dependent and independent
TNF-induced breast cancer cell death: the role of reactive oxygen
species. Ann N Y Acad Sci. 1010:437–440. 2003.
|
|
51
|
Weitsman GE, Koren R, Zuck E, et al:
Vitamin D sensitizes breast cancer cells to the action of H2O2:
mitochondria as a convergence point in the death pathway. Free
Radic Biol Med. 39:266–278. 2005.
|
|
52
|
Jiang F, Bao J, Li P, et al: Induction of
ovarian cancer cell apoptosis by 1,25-Dihydroxyvitamin D3 through
the down-regulation of telomerase. J Biol Chem. 279:53213–53221.
2004.
|
